Estimaciones de analistas de Wall Street para Ocugen, Inc. (OCGN): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 5 |
| Mantener | 1 |
| Venta | 0 |
| Venta fuerte | 0 |
| Analistas totales | 6 |
| Calificación media (1-5) | 0.83 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-04 | $-0.06 | ||
| 2026-08-06 | $-0.07 | $-0.05 | -31.3% |
| 2026-05-05 | $-0.06 | $-0.05 | -20.0% |
| 2026-03-04 | $-0.06 | $-0.06 | +0.0% |
| 2025-11-05 | $-0.07 | $-0.06 | -21.7% |
| 2025-08-01 | $-0.05 | $-0.06 | +16.7% |
| 2025-05-09 | $-0.05 | $-0.06 | +16.7% |
| 2025-03-05 | $-0.05 | $-0.05 | +0.0% |
Ratios de valoración
| Precio / Valor contable | -20.88 |
| EV / EBITDA | -6.40 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | 0 | 0 | 0 | 0 | $43000 | 0 | $2.5M | $6.0M | $4.1M | $4.4M |
| Coste de Ventas | $1.7M | $1.5M | $49623 | $8.1M | $6.4M | 0 | 0 | $704000 | $2.0M | $2.4M |
| Beneficio Bruto | -$1.7M | -$1.5M | -$49623 | -$8.1M | -$6.3M | 0 | $2.5M | $5.3M | $2.1M | $2.0M |
| I+D | $21.6M | $15.6M | $15.6M | $8.1M | $13.4M | $35.1M | $56.2M | $39.6M | $32.1M | $39.8M |
| Generales y Administrativos | $8.5M | $9.4M | $10.2M | $6.1M | $8.0M | $22.9M | $35.4M | $32.0M | $26.7M | $27.6M |
| Gastos Operativos | $30.1M | $24.9M | $25.8M | $6.1M | $15.0M | $58.0M | $91.6M | $70.9M | $56.8M | $64.9M |
| Beneficio Operativo | -$30.3M | -$24.9M | -$30.1M | -$14.2M | -$21.3M | -$58.0M | -$89.1M | -$65.5M | -$54.8M | -$62.9M |
| EBITDA | -$11.4M | -$24.9M | -$14.4M | -$14.1M | -$14.2M | -$58.1M | -$86.3M | -$62.4M | -$52.1M | -$60.3M |
| Gastos por Intereses | -$60000 | $134000 | $163000 | $1.8M | $720963 | $79000 | 0 | 0 | 0 | $5.2M |
| Beneficio Antes de Impuestos | -$16.2M | -$26.4M | -$8.6M | -$20.2M | -$21.8M | -$58.4M | -$86.8M | -$63.1M | -$54.1M | -$67.8M |
| Impuestos | 0 | -$186000 | -$15.8M | 0 | 0 | -$52000 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$16.2M | -$26.4M | -$8.6M | -$20.2M | -$21.8M | -$58.4M | -$86.8M | -$63.1M | -$54.1M | -$67.8M |
| BPA | $-68.21 | $-69.91 | $-13.98 | $-1.53 | $-0.31 | $-0.30 | $-0.40 | $-0.26 | $-0.20 | $-0.23 |
| BPA Diluido | $-67.58 | $-69.91 | $-13.98 | $-1.53 | $-0.31 | $-0.30 | $-0.40 | $-0.26 | $-0.20 | $-0.23 |
| Acciones en Circulación (Diluidas) | $239824 | $377837 | $618182 | $13.9M | $112.2M | $195.0M | $214.6M | $244.3M | $271.0M | $300.2M |
Precio
| Precio | $1.00 |
| Capitalización | $339M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ADCT · ALMS · CMPX · FULC · LCTX · LXRX · NGNE
Explorar sector: Healthcare · Biotechnology
Más secciones de OCGN: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones